Center for Medical Biotechnologies, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
Laboratory for Cellular Biotechnologies, Scientific Research Institute for Fundamental and Clinical Immunology, Novosibirsk, Russia.
Hum Vaccin Immunother. 2019;15(12):2903-2909. doi: 10.1080/21645515.2019.1614396. Epub 2019 May 22.
: We studied direct effects of human granulocyte-macrophage colony stimulating factor (GM-CSF) on phenotypical characteristics and cytokine-production of non-activated and activated human monocytes/macrophages (Mc/Mphs) and T cells.: Purified Mc/Mphs were activated by bacterial lipopolysaccharide (LPS, 1 μg/ml) for 24 h, while T cells were activated by particles conjugated and antibodies (Abs) against human CD2, CD3, and CD28 for 48 h.: GM-CSF treatment (0.01-10 ng/ml) was shown to reduce percentages of CD197 (CCR7)-positive cells in non-activated Mph cultures, without affecting significantly CD14 (LPS co-receptor), CD16 (FcγRIII, low-affinity Fc-receptor), CD119 (interferon-gamma receptor 1), and CD124 (IL4 receptor α-subunit) cells. In addition, GM-CSF reduced relative numbers of CD197 cells, as well as CD14, CD16, and CD119 cells in activated Mph cultures without affecting CD124 cell distribution. GM-CSF at the highest dose of 10 ng/ml enhanced TNF-α and IL-6 (but not IL-1β and IL-10) production in activated Mc/Mphs. In activated T cell cultures, GM-CSF at 0.1-1.0 ng/ml augmented CD38 cell numbers in naïve СD45RA/СD197 and central memory СD45RA/СD197 cell subsets, with no effect on effector СD45RA/СD197 and terminally differentiated effector СD45RA/СD197 cells. GM-CSF at a low dose (0.01 ng/ml) down-regulated INF-γ production, while at a high dosage (10.0 ng/ml) up-regulated IL-2 and IL-4 production.: In general, the results suggest that GM-CSF is able to facilitate the implication of both Mph and T cells in the adaptive immunogenesis.
我们研究了人粒细胞-巨噬细胞集落刺激因子(GM-CSF)对非激活和激活的人单核细胞/巨噬细胞(Mc/Mphs)和 T 细胞表型特征和细胞因子产生的直接影响。纯化的 Mc/Mphs 被细菌脂多糖(LPS,1μg/ml)激活 24 小时,而 T 细胞被与抗人 CD2、CD3 和 CD28 的颗粒偶联和抗体(Abs)激活 48 小时。结果表明,GM-CSF 处理(0.01-10ng/ml)可降低非激活 Mph 培养物中 CD197(CCR7)阳性细胞的百分比,而对 CD14(LPS 共受体)、CD16(FcγRIII,低亲和力 Fc 受体)、CD119(干扰素-γ受体 1)和 CD124(IL4 受体 α 亚单位)细胞没有显著影响。此外,GM-CSF 减少了激活的 Mph 培养物中 CD197 细胞以及 CD14、CD16 和 CD119 细胞的相对数量,而不影响 CD124 细胞的分布。GM-CSF 在最高剂量 10ng/ml 时增强了激活的 Mc/Mphs 中 TNF-α 和 IL-6(但不是 IL-1β 和 IL-10)的产生。在激活的 T 细胞培养物中,GM-CSF 在 0.1-1.0ng/ml 时增加了幼稚 CD45RA/CD197 和中央记忆 CD45RA/CD197 细胞亚群中 CD38 细胞的数量,对效应 CD45RA/CD197 和终末分化效应 CD45RA/CD197 细胞没有影响。GM-CSF 在低剂量(0.01ng/ml)下调 IFN-γ 的产生,而在高剂量(10.0ng/ml)上调 IL-2 和 IL-4 的产生。总的来说,这些结果表明 GM-CSF 能够促进 Mc/Mph 和 T 细胞在适应性免疫发生中的参与。